New Humira Commercial 2025

New Humira Commercial 2025. Beginning in 2025, express scripts will remove humira (adalimumab) from its commercial formularies, favoring instead several biosimilars. The launch of the first biosimilar of humira (adalimumab) last year was a major opportunity to increase patient access to, and lower the costs of, one of the bestselling drugs in the u.s.

However, despite competition from 14. Express scripts, cigna group’s pharmacy benefit manager, will have several biosimilar.